The RALES study demonstrated that spironolactone, a steroidal MR antagonist, added on top of an angiotensin-converting enzyme inhibitor in patients with severe heart failure reduces overall morbidity and mortality [3]. The gene discussed is NR3C2; the disease is heart failure.